Stock ABS ARTERRA BIOSCIENCE S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Arterra Bioscience S.p.A.

Equities

ABS

IT0005386369

Biotechnology & Medical Research

Market Closed - Borsa Italiana
Other stock markets
 11:44:59 2024-07-12 am EDT 		5-day change 1st Jan Change
2.14 EUR -2.73% Intraday chart for Arterra Bioscience S.p.A. -0.93% +28.92%
Jul. 02 Futures bearish; Lagarde confirms caution AN
Jul. 01 Mib and CAC the best after French vote AN

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 24.8 18.74 19.07 14.38 11.05
Enterprise Value (EV) 1 21.14 15.01 14.87 8.88 7.753
P/E ratio 28.9 x - - - 10.3 x
Yield - - 1.72% 4.63% 6.02%
Capitalization / Revenue 9.04 x 4.49 x 4.02 x 2.99 x 3.31 x
EV / Revenue 7.7 x 3.6 x 3.14 x 1.85 x 2.32 x
EV / EBITDA 44.7 x 9.37 x 8.57 x 4.16 x 4.87 x
EV / FCF -43.6 x -22.8 x -183 x 7 x 15.5 x
FCF Yield -2.29% -4.39% -0.55% 14.3% 6.45%
Price to Book 3.49 x - - - 1.03 x
Nbr of stocks (in thousands) 6,545 6,575 6,575 6,658 6,658
Reference price 2 3.790 2.850 2.900 2.160 1.660
Announcement Date 4/10/20 6/7/21 4/13/22 4/14/23 6/26/24
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 2.451 2.745 4.173 4.742 4.805 3.336
EBITDA 1 0.608 0.4729 1.602 1.735 2.133 1.591
EBIT 1 0.5346 0.1766 1.201 1.248 1.601 1.059
Operating Margin 21.81% 6.43% 28.79% 26.32% 33.31% 31.75%
Earnings before Tax (EBT) 1 1.073 0.9405 1.199 1.274 1.797 1.302
Net income 1 1.044 0.8572 1.109 1.111 1.414 1.076
Net margin 42.59% 31.23% 26.57% 23.42% 29.43% 32.26%
EPS 2 0.2085 0.1310 - - - 0.1616
Free Cash Flow 1 -0.3489 -0.4847 -0.6592 -0.0813 1.269 0.5001
FCF margin -14.23% -17.66% -15.8% -1.71% 26.41% 14.99%
FCF Conversion (EBITDA) - - - - 59.51% 31.43%
FCF Conversion (Net income) - - - - 89.76% 46.47%
Dividend per Share - - - 0.0500 0.1000 0.1000
Announcement Date 10/24/19 4/10/20 6/7/21 4/13/22 4/14/23 6/26/24
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 0.16 - - - - -
Net Cash position 1 - 3.67 3.73 4.2 5.5 3.3
Leverage (Debt/EBITDA) 0.2551 x - - - - -
Free Cash Flow 1 -0.35 -0.48 -0.66 -0.08 1.27 0.5
ROE (net income / shareholders' equity) 48.8% 17.7% 14.5% 12.6% 14.2% 10.1%
ROA (Net income/ Total Assets) 8.1% 1.54% 7.55% 7.12% 8.28% 5.27%
Assets 1 12.89 55.66 14.67 15.59 17.07 20.42
Book Value Per Share 2 0.5100 1.090 - - - 1.610
Cash Flow per Share 2 0.1500 0.7100 - - - 0.5500
Capex 1 0.45 0.84 0.34 0.54 0.09 0.07
Capex / Sales 18.23% 30.76% 8.2% 11.41% 1.96% 1.98%
Announcement Date 10/24/19 4/10/20 6/7/21 4/13/22 4/14/23 6/26/24
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ARTERRA BIOSCIENCE S.P.A. Stock Arterra Bioscience S.p.A.
+28.92% 15.54M
MODERNA, INC. Stock Moderna, Inc.
+22.10% 46.55B
LONZA GROUP AG Stock Lonza Group AG
+46.45% 41.84B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.12% 40.84B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+36.10% 32.95B
CELLTRION, INC. Stock Celltrion, Inc.
-6.30% 28.27B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+18.71% 27.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+46.15% 14.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+44.52% 13.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.19% 12.18B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ABS Stock
  4. Financials Arterra Bioscience S.p.A.